We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Edwards Lifesciences (EW - Free Report) appears well-positioned to continue benefiting from the expanding adoption of its premium surgical technologies worldwide. The Transcatheter Mitral and Tricuspid Therapies (“TMTT”) business has seen consistent growth over the past few quarters, which is highly encouraging. The company’s TAVR platform represents another significant growth opportunity, supported by patient activation and advanced new technologies. However, ongoing macroeconomic pressures and currency swings could weigh on Edwards’ financial results.
Over the past year, this Zacks Rank #3 (Hold) stock has gained 13% against the 5.5% fall of the industry and the S&P 500 composite’s 23.8% growth.
The renowned global medical device company has a market capitalization of $49.51 billion. EW’s earnings yield of 3.5% favorably compares with the industry’s negative 3.4% yield. In the trailing four quarters, Edwards delivered an average earnings surprise of 4.8%.
Let’s delve deeper.
Upsides for EW Stock
Surgical Structural Heart, A Promising Business: The business pioneered the innovative RESILIA tissue, which is backed by more than 40 years of the company’s tissue technology leadership. In first-quarter 2026, the segment grew 6% from the prior-year level, driven by strong global adoption of Edwards’ premium resilient technologies, including INSPIRIS, MITRIS and KONECT. The company continues to see positive procedure growth globally for the many patients treated surgically, including those undergoing complex procedures.
Edwards has been continuously generating evidence to expand the RESILIA portfolio, including positive one-year results from MOMENTIS, supporting the long-term durability of MITRIS systems for surgical mitral valve replacement. It also unveiled favorable eight-year data showing the strong durability of RESILIA tissue bioprosthetic valves.
Image Source: Zacks Investment Research
TMTT Portfolio Holds Potential: To transform care and unlock the significant long-term growth opportunity for mitral and tricuspid patients, Edwards focuses on three key value drivers — a portfolio of differentiated therapies for complex mitral and tricuspid anatomies, positive clinical trial results to support approvals and adoption, and favorable real-world clinical outcomes. In the first quarter of 2026, the segment witnessed an approximately 42% increase in sales compared with the prior year, driven by the continued global adoption of PASCAL, EVOQUE and SAPIEN M3 systems.
Edwards is making strides with the EVOQUE commercial rollout, activating new sites in both the United States and Europe (other than initial trial centers). At the recent ACC session, two-year TRISCEND II data showed EVOQUE significantly reduced all-cause mortality versus medical therapy while delivering sustained TR elimination, improved health and quality of life and no added device-related risk. Owing to a strong global uptake of differentiated therapies, the company now expects to achieve $2.00 billion of sales in 2030.
Solid TAVR Opportunities: Edwards expects TAVR platform growth to be propelled by greater awareness, patient activation, advances in new technologies such as RESILIA, as well as indication expansion and increased global adoption. In the first quarter of 2026, TAVR sales exceeded $1 billion for the sixth consecutive quarter, with 11% year-over-year growth. The performance reflects clinicians' elevated focus on SAPIEN therapy and proactive disease management of patients suffering from severe aortic stenosis. Edwards' strong competitive position and average selling prices remained stable globally.
Europe’s sales benefited from healthy underlying TAVR procedure growth. The updated guidelines from the European Society of Cardiology and the European Association for Cardiothoracic Surgery are also reinforcing the role of TAVR for a broader patient population. Outside Europe, sales grew strongly across several regions, including Japan, driven by rising procedure volumes and increased adoption of the SAPIEN 3 Ultra RESILIA platform.
What Ails Edwards?
Macro Concerns Put Pressure on the Bottom Line: Edwards’ extensive global operations and overseas manufacturing facilities and suppliers bring certain financial, economic, political and other risks. The global economy continues to experience volatility and disruptions, including conditions impacting inflation, credit and capital markets, interest rates and factors influencing overall economic stability and the political environment relating to health care. Persistent inflationary pressure, supply constraints stemming from geopolitical complications and regulatory changes are weighing heavily on the company’s operating results. Hospital staffing shortages remain another bottleneck.
Foreign Exchange Headwinds: Foreign exchange is a major headwind for Edwards due to a considerable percentage of its revenues coming from outside the United States (in 2025, 41.6% of the company’s net sales were derived from international regions). We remain worried about the significant challenges Edwards had to face owing to the unfavorable foreign currency impact that has been adversely affecting the company’s gross margin over the past few quarters.
EW Stock Estimate Trend
The Zacks Consensus Estimate for Edwards’ 2026 earnings per share (EPS) has remained constant at $3.00 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $6.74 billion, suggesting an 11.1% improvement from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
Globus Medical has an earnings yield of 5.9% compared to the industry’s negative 3.2% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 33.8% against the industry’s 5.5% fall over the past year.
Align Technology, sporting a Zacks Rank #1, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 9.6% growth. Shares of the company have dropped 2.9% against the industry’s 6.9% rise. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2 (Buy), has an earnings yield of 14.2% against the industry’s negative 3.2% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 37.9% against the industry’s 5.5% decline over the past year.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Should You Continue to Hold EW Stock in Your Portfolio?
Key Takeaways
Edwards Lifesciences (EW - Free Report) appears well-positioned to continue benefiting from the expanding adoption of its premium surgical technologies worldwide. The Transcatheter Mitral and Tricuspid Therapies (“TMTT”) business has seen consistent growth over the past few quarters, which is highly encouraging. The company’s TAVR platform represents another significant growth opportunity, supported by patient activation and advanced new technologies. However, ongoing macroeconomic pressures and currency swings could weigh on Edwards’ financial results.
Over the past year, this Zacks Rank #3 (Hold) stock has gained 13% against the 5.5% fall of the industry and the S&P 500 composite’s 23.8% growth.
The renowned global medical device company has a market capitalization of $49.51 billion. EW’s earnings yield of 3.5% favorably compares with the industry’s negative 3.4% yield. In the trailing four quarters, Edwards delivered an average earnings surprise of 4.8%.
Let’s delve deeper.
Upsides for EW Stock
Surgical Structural Heart, A Promising Business: The business pioneered the innovative RESILIA tissue, which is backed by more than 40 years of the company’s tissue technology leadership. In first-quarter 2026, the segment grew 6% from the prior-year level, driven by strong global adoption of Edwards’ premium resilient technologies, including INSPIRIS, MITRIS and KONECT. The company continues to see positive procedure growth globally for the many patients treated surgically, including those undergoing complex procedures.
Edwards has been continuously generating evidence to expand the RESILIA portfolio, including positive one-year results from MOMENTIS, supporting the long-term durability of MITRIS systems for surgical mitral valve replacement. It also unveiled favorable eight-year data showing the strong durability of RESILIA tissue bioprosthetic valves.
Image Source: Zacks Investment Research
TMTT Portfolio Holds Potential: To transform care and unlock the significant long-term growth opportunity for mitral and tricuspid patients, Edwards focuses on three key value drivers — a portfolio of differentiated therapies for complex mitral and tricuspid anatomies, positive clinical trial results to support approvals and adoption, and favorable real-world clinical outcomes. In the first quarter of 2026, the segment witnessed an approximately 42% increase in sales compared with the prior year, driven by the continued global adoption of PASCAL, EVOQUE and SAPIEN M3 systems.
Edwards is making strides with the EVOQUE commercial rollout, activating new sites in both the United States and Europe (other than initial trial centers). At the recent ACC session, two-year TRISCEND II data showed EVOQUE significantly reduced all-cause mortality versus medical therapy while delivering sustained TR elimination, improved health and quality of life and no added device-related risk. Owing to a strong global uptake of differentiated therapies, the company now expects to achieve $2.00 billion of sales in 2030.
Solid TAVR Opportunities: Edwards expects TAVR platform growth to be propelled by greater awareness, patient activation, advances in new technologies such as RESILIA, as well as indication expansion and increased global adoption. In the first quarter of 2026, TAVR sales exceeded $1 billion for the sixth consecutive quarter, with 11% year-over-year growth. The performance reflects clinicians' elevated focus on SAPIEN therapy and proactive disease management of patients suffering from severe aortic stenosis. Edwards' strong competitive position and average selling prices remained stable globally.
Europe’s sales benefited from healthy underlying TAVR procedure growth. The updated guidelines from the European Society of Cardiology and the European Association for Cardiothoracic Surgery are also reinforcing the role of TAVR for a broader patient population. Outside Europe, sales grew strongly across several regions, including Japan, driven by rising procedure volumes and increased adoption of the SAPIEN 3 Ultra RESILIA platform.
What Ails Edwards?
Macro Concerns Put Pressure on the Bottom Line: Edwards’ extensive global operations and overseas manufacturing facilities and suppliers bring certain financial, economic, political and other risks. The global economy continues to experience volatility and disruptions, including conditions impacting inflation, credit and capital markets, interest rates and factors influencing overall economic stability and the political environment relating to health care. Persistent inflationary pressure, supply constraints stemming from geopolitical complications and regulatory changes are weighing heavily on the company’s operating results. Hospital staffing shortages remain another bottleneck.
Foreign Exchange Headwinds: Foreign exchange is a major headwind for Edwards due to a considerable percentage of its revenues coming from outside the United States (in 2025, 41.6% of the company’s net sales were derived from international regions). We remain worried about the significant challenges Edwards had to face owing to the unfavorable foreign currency impact that has been adversely affecting the company’s gross margin over the past few quarters.
EW Stock Estimate Trend
The Zacks Consensus Estimate for Edwards’ 2026 earnings per share (EPS) has remained constant at $3.00 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $6.74 billion, suggesting an 11.1% improvement from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
Globus Medical has an earnings yield of 5.9% compared to the industry’s negative 3.2% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 33.8% against the industry’s 5.5% fall over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology, sporting a Zacks Rank #1, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 9.6% growth. Shares of the company have dropped 2.9% against the industry’s 6.9% rise. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2 (Buy), has an earnings yield of 14.2% against the industry’s negative 3.2% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 37.9% against the industry’s 5.5% decline over the past year.